Skip to content
News

European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

ORSERDU is based on technology licensed out of the lab of Dr. Donald McDonnell (Pharmacology and Cancer Biology, SOM).